)
Pulse Biosciences (PLSE) investor relations material
Pulse Biosciences Stifel 2026 Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Technology and market opportunity
nsPFA uses pulse durations 1,000x shorter than microsecond PFA, with higher voltage amplitude; management says the distinct energy creates a different tissue mechanism of action.
Issued patents increased by 30, or more than 10%, this year; the platform has a 285-patent portfolio covering waveforms, methods and catheter design.
U.S. AF ablation market cited at $4B, with potential to approach $10B in the early 2030s; the market is projected to more than double over 5–7 years.
Feasibility workflow averaged 12 five-second applications; management cited faster procedures and potential for 2–3 additional cases per room daily, with $23,000 revenue per case for the service line.
Clinical evidence and regulatory plans
Paroxysmal AF feasibility results: 100% freedom from AF off drugs at 6 months, 96% at 12 months, and 90% freedom from all atrial arrhythmias at 12 months.
The pivotal paroxysmal AF IDE enrolled its final patient in October, in under 180 days; six-month data were expected by April, with a clinical module submission planned for early Q3 2027.
Management expects U.S. approval early in 2028, based on an estimated six-month FDA review; CE mark is expected in H2 2027.
A 100-patient, one-year follow-up update is targeted for Q1 at an AF conference; a persistent AF IDE filing is planned for Q4, with study start early the following year.
Pipeline and commercialization
A cardiac surgery IDE is enrolling patients with preoperative AF; additional European trials are planned to expand clinical experience.
Thyroid nodule treatment targets procedures that may preserve thyroid function; management described a 30–45-minute procedure with same-day discharge.
A next-generation catheter is planned to combine regional and focal ablation in one device; mapping integration has been demonstrated with Abbott EnSite X.
Management is preparing for a strategic partnership-led commercial approach while retaining the option to operate independently; manufacturing startup investment is beginning ahead of a potential 2028 launch at scale.
Cash and marketable securities totaled $189M at the prior quarter-end; management’s goal is to exit the year closer to $200M.
- Pivotal AF enrollment finished early as cash reserves rose to $189.2M.PLSE
Q3 2026 - nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption.PLSE
Canaccord Genuity's 46th Annual Growth Conference - nsPFA delivers superior ablation outcomes with robust IP and strong clinical and financial momentum.PLSE
Investor presentation - Pivotal trial enrollment accelerated, cash rose to $101.6M, and net loss reached $24.7M.PLSE
Q2 2026 - Directors and auditor ratified as company advances AFib trial and strengthens leadership.PLSE
AGM 2026 - Nanosecond PFA platform shows superior efficacy and is on track for early 2028 launch.PLSE
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Nanosecond PFA shows strong clinical promise in AFib, with accelerated pivotal study progress.PLSE
Bank of America Global Healthcare Conference 2026 - Accelerated pivotal trial progress, strong data, and $18.6M net loss with $0.4M revenue.PLSE
Q1 2026 - Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue.PLSE
Q4 2025
)
)
)
)
)
)
)
)